1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)

Several companies including argenx, Sanofi/Regeneron, and AstraZeneca are seeking to improve Bullous Pemphigoid standard of care by pursuing label expansions for their existing antibody-based therapies. NEWTON, Mass., March 16, 2023 /PRNewswire/ — Bullous pemphigoid (BP) is a rare,…